A brighter side to thalidomide: its potential use in immunological disorders

Millrine, David ORCID: https://orcid.org/0000-0002-8041-0151 and Kishimoto, Tadamitsu 2017. A brighter side to thalidomide: its potential use in immunological disorders. Trends in Molecular Medicine 23 (4) , pp. 348-361. 10.1016/j.molmed.2017.02.006

Preview

PDF - Accepted Post-Print Version Download (928kB) | Preview

Abstract

Thalidomide and its derivatives are immunomodulatory drugs (IMiDs) known for their sedative, teratogenic, anti-angiogenic, and anti-inflammatory properties. Commonly used in the treatment of cancers such as Multiple Myeloma and Myelodysplastic Syndrome, IMiDs have also been used in the treatment of an inflammatory skin pathology associated with Hansen’s disease/Leprosy and show promise in the treatment of autoimmune disorders including Systemic Lupus Erythmatosus and Inflammatory Bowel Disease. Recent structural and experimental observations have revolutionized our understanding of these properties by revealing the fundamental molecular events underpinning IMiD activity. Here, we review these findings, their relevance to IMiD therapy in immunological disorders, and discuss how further research might unlock the vast clinical potential of these compounds.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Elsevier
ISSN:	1471-4914
Date of First Compliant Deposit:	27 July 2017
Last Modified:	06 Nov 2023 22:48
URI:	https://orca.cardiff.ac.uk/id/eprint/101798

Citation Data

Cited 60 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item